Merck’s Capvaxive shows strong momentum amid industry vaccine decline
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Subscribe To Our Newsletter & Stay Updated